149|128|Public
25|$|The major {{industries}} include textiles, hydrocarbon {{and chemical}} production, and <b>generic</b> <b>pharmaceutical</b> production. Unemployment is high at about 10.5%.|$|E
25|$|In 2014, {{according}} to an analysis by the <b>Generic</b> <b>Pharmaceutical</b> Association, generic drugs accounted for 88% of the 4.3 billion prescriptions filled in the United States.|$|E
25|$|The drug's US patent will {{expire in}} 2020. In May 2012, the US District Court of Delaware passed an order {{in favour of}} OSI Pharmaceutical LLC against Mylan Pharmaceuticals {{upholding}} {{the validity of the}} patent for Erlotinib. In India, <b>generic</b> <b>pharmaceutical</b> firm Cipla is battling with Roche against the Indian patent for this drug.|$|E
5000|$|... 1995 - Mallinckrodt {{established}} <b>generic</b> <b>pharmaceuticals</b> business ...|$|R
5000|$|... #Subtitle level 3: Expanding {{access to}} <b>generic</b> <b>pharmaceuticals</b> ...|$|R
5000|$|Upsher-Smith offers <b>generic</b> <b>pharmaceuticals</b> {{to treat}} the {{following}} disease states: ...|$|R
2500|$|On March 31, 2009, the FDA {{announced}} another generic digoxin pill recall by posting {{this company}} press release on the agency's web site: [...] "Caraco Pharmaceutical Laboratories, Ltd. Announces a Nationwide Voluntary Recall of All Lots of Digoxin Tablets Due to Size Variability". A March 31 press release from Caraco, a <b>generic</b> <b>pharmaceutical</b> company, stated: ...|$|E
5000|$|Lupin Limited is a {{transnational}} {{pharmaceutical company}} based in Mumbai. It is the seventh-largest [...] company by market capitalization; and the 10th-largest <b>generic</b> <b>pharmaceutical</b> company by revenue [...] globally. Lupin is the fifth-largest <b>generic</b> <b>pharmaceutical</b> company in the US by prescription-led market share [...] and 3rd largest Indian pharmaceutical company by revenue. [...] It has {{the distinction of being}} the fastest growing <b>generic</b> <b>pharmaceutical</b> player in the US and Japan;, and is the 4th largest and the fastest growing <b>generic</b> <b>pharmaceutical</b> player in South Africa.|$|E
50|$|GPhA is the U.S. {{representative}} to the International Generic and Biosimilar Medicines Association (IGBA), which advocates global interests of the <b>generic</b> <b>pharmaceutical</b> industry in collaborates with the Canadian <b>Generic</b> <b>Pharmaceutical</b> Association, Medicines for Europe, Japan Generic Medicines Association, and other IGBA members.|$|E
50|$|Heritage Pharmaceuticals is a {{manufacturer}} of <b>generic</b> <b>pharmaceuticals</b> based in Eatontown, New Jersey and established in 2006.|$|R
5000|$|Industry {{sponsors}} {{of human and}} veterinary (<b>pharmaceuticals,</b> <b>generic</b> <b>pharmaceuticals,</b> biologics, devices, over-the-counter) products submitted to the FDA.|$|R
5000|$|Akorn Pharmaceuticals (...) is an American <b>generic</b> <b>pharmaceuticals</b> {{manufacturer}} {{based in}} Lake Forest, Illinois, US. It is {{a component of}} the NASDAQ Biotechnology Index.|$|R
50|$|Apotex is {{a member}} of The Canadian <b>Generic</b> <b>Pharmaceutical</b> Association (CGPA), the <b>Generic</b> <b>Pharmaceutical</b> Association (GPhA), an {{associate}} member of the Canadian Animal Health Institute (CAHI), the Canadian Association for Pharmacy Distribution Management (CAPDM), as well as the Greater Toronto Area's Partners in Project Green.|$|E
5000|$|By 28 yeas to 67 nays, Bingaman Amendment No. 2111, to {{allegedly}} provide {{cost savings}} by fostering competition among <b>generic</b> <b>pharmaceutical</b> manufacturers {{and ensuring that}} anti-competitive [...] "pay-for-delay" [...] settlements between brand-name and <b>generic</b> <b>pharmaceutical</b> manufacturers do not block generic drugs from entering the market.|$|E
5000|$|Docpharma - <b>generic</b> <b>pharmaceutical</b> {{distribution}} {{company in}} Belgium, the Netherlands and Luxembourg ...|$|E
50|$|Ratiopharm {{was owned}} by Adolf Merckle and makes <b>generic</b> <b>Pharmaceuticals.</b> They are based in Ulm, Germany and {{products}} being distributed in over 35 countries worldwide.|$|R
50|$|Lannett in its {{acquisition}} for $1.23 {{billion in}} cash, plus additional contingent consideration, of Kremers Urban Pharmaceuticals, the U.S. specialty <b>generic</b> <b>pharmaceuticals</b> subsidiary of global biopharmaceuticals company UCB.|$|R
50|$|Teva Pharmaceuticals {{develops}} {{and markets}} <b>generic</b> <b>pharmaceuticals</b> under various brand names, including the Barr Laboratories, Inc. label. Teva Pharmaceuticals {{is the largest}} generic drug manufacturer in the world.|$|R
5000|$|... to {{encourage}} the formation of <b>generic</b> <b>pharmaceutical</b> and biosimilar associations in countries where they do not yet exist ...|$|E
50|$|The major {{industries}} include textiles, hydrocarbon {{and chemical}} production, and <b>generic</b> <b>pharmaceutical</b> production. Unemployment is high at about 10.5%.|$|E
50|$|Actavis, plc also {{operates}} the world's third-largest generics business. The company is {{ranked in the}} top 3 in 12 global markets, the top 5 in 16 global markets, and in the top 10 in 33 global markets. Actavis also develops and out-licenses <b>generic</b> <b>pharmaceutical</b> products outside the U.S. through its Medis third-party business, the world's largest <b>generic</b> <b>pharmaceutical</b> out-licensing business. Medis has more than 300 customers globally, and offers more than 200 products. Actavis, plc is also developing biosimilars products in oncology and other therapeutic categories, and currently has five biosimilar products in development. Actavis, plc has more than 40 manufacturing and distribution facilities around the world, with a capacity of approximately 40 billion units annually. Actavis Global Operations also includes Anda, Inc., the fourth-largest U.S. <b>generic</b> <b>pharmaceutical</b> product distributor in the United States.|$|E
50|$|Roche Products v. Bolar Pharmaceutical, 733 F.2d 858 (Fed. Cir. 1984), was a {{court case}} in the United States related to the {{manufacturing}} of <b>generic</b> <b>pharmaceuticals.</b> See Research exemption.|$|R
50|$|Yusuf Khwaja Hamied (born 25 July 1936) is {{a billionaire}} Indian {{scientist}} and businessman, {{the chairman of}} Cipla, a <b>generic</b> <b>pharmaceuticals</b> company founded by his father Khwaja Abdul Hamied in 1935.|$|R
50|$|Troyan is {{the home}} of the large Actavis http://www.actavis.bg/ <b>generic</b> <b>pharmaceuticals</b> plant as well as the light {{machinery}} factories Elma and Mashstroihttp://www.mashstroy.bg. There is located also plywood mill Welde. Another major industry is the famous plum brandy (slivova rakia) production brewery Vinprom-Troyan.|$|R
50|$|The {{objectives}} of the Association are, without profit purpose, to represent, support and develop the common scientific and technical interests of the <b>generic</b> <b>pharmaceutical</b> industry and the biosimilar industry or national or European associations of such, firms, companies or other legal bodies active in the <b>generic</b> <b>pharmaceutical</b> or the biosimilar industries. Those interests shall include, but shall not be restricted to, developments within the European Union, Europe {{as a whole and}} relations between the European Union and third countries.|$|E
5000|$|... and lastly, {{through its}} general activities, {{to seek to}} promote {{progress}} in the <b>generic</b> <b>pharmaceutical</b> and biosimilar industries by quality improvements in products ...|$|E
50|$|Incepta Pharmaceuticals Limited is a <b>generic</b> <b>pharmaceutical</b> {{company based}} in Dhaka, Bangladesh, which {{manufactures}} and markets medicinal drugs. Abdul Muktadir {{is the chairman of}} the company.|$|E
50|$|By {{late fall}} of the same year, the company moved to Southern California into an initial 2,000-square-foot (190 m2) leased {{facility}} in Corona, and the development and manufacturing of <b>generic</b> <b>pharmaceuticals</b> began. The Corona site became the corporate headquarters for the rapidly expanding U.S. company.|$|R
50|$|The Snyders {{played a}} major role in {{establishing}} the standards and approval process with the U.S. Food and Drug Administration for <b>generic</b> <b>pharmaceuticals.</b> In 1991, Snyder expressed his concerns regarding FDA approval processes that had multiple chemists raising issues regarding generic versions of brand-name drugs.|$|R
5000|$|Simcere Pharmaceutical Group or Simcere Pharmaceutical (...) is a {{manufacturer}} and supplier of branded <b>generic</b> <b>pharmaceuticals</b> in the Chinese market. Its focus is to introduce <b>generic</b> and <b>pharmaceutical</b> {{products for the}} treatment of diseases with high incidence and/or mortality rate. The Company has introduced a generic anti-stroke medication under the brand name, Bicun, and an anti-cancer medication under the brand name, Endu. Its products include antibiotics, anti-stroke medications, anti-inflammatory drugs, anti-cancer medications and other medicines. In addition, it has obtained approvals from the China State Food and Drug Administration (SFDA) to manufacture and sell over 210 other products.|$|R
50|$|In 2014, {{according}} to an analysis by the <b>Generic</b> <b>Pharmaceutical</b> Association, generic drugs accounted for 88% of the 4.3 billion prescriptions filled in the United States.|$|E
5000|$|Pharmaceutical Product Identification (PhPID) uniquely {{identifies}} a <b>generic</b> (<b>pharmaceutical)</b> {{representation of}} a medicinal product at Levels Substance(s)/Strength(s) - Strength Units /Reference Strengths per Administrable Dose Form ...|$|E
5000|$|... 2008: Relonchem Ltd. , {{engaged in}} licensing, {{marketing}} and distribution of <b>generic</b> <b>pharmaceutical</b> products to retailers, wholesalers and hospitals in the UK, was acquired in August 2008 by Marksans.|$|E
40|$|The {{advantages}} of <b>generic</b> <b>pharmaceuticals</b> are acknowledged by policy makers worldwide, provided efficient national policies are in place, generics {{are available at}} reduced prices, drive competition and innovation, enhance access to essential medicines, ensure supply continuity, stimulate economic development, and generate savings for healthcare systems. This paper reviews the world market of <b>generic</b> <b>pharmaceuticals,</b> with special emphasis on the current situation and expected future development. Besides providing a global picture, different regions are separately examined by both assessing recent market analyses data, and by including recent literature on generics and their role in enhancing access to essential medicines. In view of the challenges in developing countries, the Republic of South Africa is dealt with in more detail. The analysis {{stresses the importance of}} this highly dynamic and competitive market, expected to continue to grow in the future, thus remaining an attractive business for new entrants, for mergers and for acquisition...|$|R
50|$|Aurobindo Pharma Limited is a {{pharmaceutical}} manufacturing company headquartered in HITEC City, Hyderabad, India. The company manufactures <b>generic</b> <b>pharmaceuticals</b> and active pharmaceutical ingredients. The company’s {{area of activity}} includes six major therapeutic/product areas: antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics. The company markets these products in over 125 countries. Its marketing partners include AstraZeneca and Pfizer.|$|R
50|$|Advent has {{acquired}} {{a number of companies}} in Central and Eastern Europe through its dedicated regional funds. These include Romanian Ceramica IASI, one of Romania’s leading ceramic bricks and clay roof tiles producers, Bolix, a leading Polish producer of construction chemicals, Dufa Deutek, Romania’s largest decorative paints producer, and LaborMed Pharma, which manufactures and distributes <b>generic</b> <b>pharmaceuticals</b> primarily for cardiovascular and central nervous system aliments.|$|R
